<div>
  <ul>
    <li>
      <p>
        French-American AI biotech company Owkin and Sanofi have extended their existing collaboration (initially entered in 
        <a href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-11-18-06-30-00-2336966">
          November 2021
        </a>
        ) to include immunology in the duo's drug discovery efforts.
      </p>
    </li>
    <li>
      <p>
        The collaboration will leverage Owkin&rsquo;s AI technology to identify gene targets and patient subpopulations within Sanofi's immunology pipeline. Integrating Owkin&rsquo;s ML and data will enable tailored therapy strategies based on the molecular and cellular characteristics of individual patients.
      </p>
    </li>
  </ul>
  <p>
  </p>
  <p>
    <b></b>
  </p>
  <p>
  </p>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.owkin.com/newsfeed/owkin-expands-collaboration-with-sanofi-leveraging-ai-for-drug-positioning-in-immunology">
      Company press release&nbsp;
    </a>
  </p>
</div>


AI Drug Discovery

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 <p>The AI biotech company of French-American origin, Owkin, has broadened its existing collaboration with Sanofi, originally established in <a href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-11-18-06-30-00-2336966"> November 2021 </a>. This expansion now includes immunology in their shared drug discovery efforts.</p>
 <p>The cooperation will utilize Owkin’s AI technology, aimed at identifying gene targets and certain patient subpopulations within Sanofi's immunology pipeline. The integration of Owkin’s Machine Learning (ML) and data will facilitate the formulation of custom therapy strategies, based specifically on the molecular and cellular traits of each patient.</p>
</div>

Owkin and Sanofi expand existing partnership for AI-driven drug discovery in immunology

Reinventing gene therapies with next-generation technologies

Human Gene Editing

<div>
 <p>California-based gene editing firm Scribe Therapeutics and Sanofi have expanded their ongoing research partnership, with a new focus on in vivo CRISPR treatments for oncology indications and genomic diseases. Initiated in <a href="https://www.biopharmadive.com/news/sanofi-scribe-gene-editing-nk-cell-therapy-cancer/632718/">September 2022 </a>, the collaboration now includes a second target. Scribe will receive payments for achieving certain milestones and additional rewards based on the program’s commercial success. The partnership will combine Scribe's CRISPR by Design, X-Editing technologies, and Sanofi's genomic research expertise.</p>
</div>

Scribe Therapeutics and Sanofi expand partnership to develop in vivo genetic therapies

<div>
<p>AI drug discovery company AQEMIA and Sanofi have entered a multi-year research collaboration to accelerate the research and development of small molecule drug candidates.</p>
<p>As part of the agreement, AQEMIA will receive an upfront payment and up to USD 140 million in milestone payments. Sanofi will be responsible for laboratory research, development, and commercial activities of the drug candidates.</p>
<p>The partnership will leverage AQEMIA's deep physics platform combined with GenAI and Sanofi’s global R&amp;D expertise to accelerate the design of novel drug molecules for Sanofi’s selected therapeutic targets.</p>
</div>

AQEMIA and Sanofi collaborate to discover small-molecule drug candidates

Managing employee health-related benefits

Health Benefits Platforms

DISRUPTOR_PRESENT

<div>
 <ul>
  <li><p>GoodRx has partnered with Sanofi to offer a lower price on Sanofi's insulin drug, Lantus.</p></li>
  <li><p>Lantus is now available for $35 for a 30-day supply, regardless of insurance status.</p></li>
  <li><p>This partnership is part of GoodRx's mission to provide savings for patients by working with various pharmaceutical manufacturers.</p></li>
 </ul>
</div>

GoodRx partners with Sanofi to discount insulin drug for all prescription holders

Novel therapies to reboot cells and organs

Cell & Gene Therapy

The New York-based gene therapy company, MeiraGTx, has received a USD 30 million strategic investment from Sanofi. Sanofi purchased 4.0 million ordinary shares at a rate of USD 7.50 per share. As part of the transaction, Sanofi will have a right of first negotiation for the use of MeiraGTx's gene regulation technology in immunology, inflammation, and Central Nervous System targets. They will also have the same right for MeiraGTx's Phase II Xerostomia program.

MeiraGTx secures USD 30 million investment from Sanofi

BioMap, a Chinese AI research company, has partnered with pharma giant Sanofi to develop AI modules for biotherapeutic drug discovery. This collaboration will combine BioMap's AI platform with Sanofi's data and expertise to create advanced AI models and protein large language models. These models will aid in the design and optimization of biologics for various therapeutic areas. The partnership includes an upfront payment of $10 million, with potential milestone payments totaling over $1 billion. BioMap aims to use its technology to accelerate drug discovery and enable multiple downstream task models with limited data, facilitating GenAI.

BioMap and Sanofi enter USD 1 billion AI deal

Scribe Therapeutics signs USD 1.2 billion expanded collaboration with Sanofi

Incorporating technology to improve efficiency and success rate of clinical trials

All Updates

Owkin and Sanofi expand existing partnership for AI-driven drug discovery in immunology

Scribe Therapeutics and Sanofi expand partnership to develop in vivo genetic therapies

AQEMIA and Sanofi collaborate to discover small-molecule drug candidates

GoodRx partners with Sanofi to discount insulin drug for all prescription holders

MeiraGTx secures USD 30 million investment from Sanofi

BioMap and Sanofi enter USD 1 billion AI deal

Scribe Therapeutics signs USD 1.2 billion expanded collaboration with Sanofi

Sanofi partners with THREAD for decentralized clinical trial management

Insilico Medicine and Sanofi sign a USD 1.2 billion AI deal

Atomwise and Sanofi enter into USD 1.2 billion AI deal

All Updates

Owkin and Sanofi expand existing partnership for AI-driven drug discovery in immunology

Scribe Therapeutics and Sanofi expand partnership to develop in vivo genetic therapies

AQEMIA and Sanofi collaborate to discover small-molecule drug candidates

GoodRx partners with Sanofi to discount insulin drug for all prescription holders

MeiraGTx secures USD 30 million investment from Sanofi

BioMap and Sanofi enter USD 1 billion AI deal

Scribe Therapeutics signs USD 1.2 billion expanded collaboration with Sanofi

Sanofi partners with THREAD for decentralized clinical trial management

​​Insilico Medicine and Sanofi sign a USD 1.2 billion AI deal

Atomwise and Sanofi enter into USD 1.2 billion AI deal

Insilico Medicine and Sanofi sign a USD 1.2 billion AI deal